Genetics Quiz: Somatic Vs Germline Mutations

What this quiz covers

This quiz focuses on Somatic Vs Germline Mutations, giving you a quick way to practice the rules, question types, and explanations that matter most for Genetics.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. The mutation is somatic and occurred independently in both of the child's eyes.
2. The condition is not genetic and was caused by an in utero environmental exposure.
3. A de novo mutation occurred in an RB1 allele in one of the parental gametes. (correct answer)
4. Both parents are carriers of a recessive RB1 allele that is not detectable by standard sequencing.

Explanation: Bilateral retinoblastoma strongly implies a germline mutation, as it would be extremely improbable for two independent somatic 'first hits' to occur, one in each eye. Since the mutation is present in all the child's cells but not in the parents' somatic DNA (blood), the most plausible explanation is a de novo mutation. This means the mutation arose for the first time in one of the parental germ cells (sperm or egg) or in the zygote shortly after fertilization.

Question 2

1. A somatic reversion mutation that provides a survival advantage to tumor cells under therapeutic pressure. (correct answer)
2. An example of epigenetic silencing that bypasses the need for BRCA2 protein.
3. A new germline mutation that corrects the original defect throughout the patient's body.
4. A passenger mutation that is unrelated to the observed drug resistance.

Explanation: When you encounter questions about cancer drug resistance involving DNA repair genes like BRCA2, focus on how tumor cells evolve under therapeutic pressure. PARP inhibitors work through synthetic lethality—they're particularly toxic to cells that already have defective homologous recombination (like those with BRCA2 mutations) because they create a "double hit" that makes DNA repair impossible. The correct answer is A because this describes exactly what happened: the tumor developed a secondary mutation that restored BRCA2's reading frame, essentially reversing the original defect. This somatic reversion occurred only in some tumor cells, giving them a survival advantage when exposed to the PARP inhibitor. These resistant cells could then proliferate while drug-sensitive cells died. Answer B is wrong because this involves a genetic mutation restoring protein function, not epigenetic changes that silence genes. Answer C misunderstands the scope—this is a somatic mutation occurring only in tumor tissue, not a new germline change affecting the whole body. Answer D incorrectly categorizes this as a passenger mutation, when it's clearly a driver of resistance since it directly counters the drug's mechanism. The key study point here is understanding that cancer is an evolutionary process. Under therapeutic pressure, tumor cells with advantageous mutations (like restored DNA repair) will be selected for survival. Always consider whether a mutation helps or hurts cancer cells in the specific treatment context—resistance mutations provide survival advantages that allow certain cell populations to thrive despite therapy.

Question 3

1. The older man's cancer likely arose from accumulated somatic mutations, while the younger man's risk is conferred by a germline mutation. (correct answer)
2. Both cancers are likely driven by the same type of somatic mutations, with family history being coincidental.
3. The older man's cancer is driven by a germline mutation, while the younger man's risk is from a somatic mutation.
4. The older man's cancer is somatic and heritable, while the younger man's cancer risk is germline but not heritable.

Explanation: When you encounter cancer genetics questions, focus on distinguishing between somatic mutations (acquired during a person's lifetime in specific cells) and germline mutations (inherited and present in all cells from birth). The key clues are age of onset, family history, and mutation testing results. The 65-year-old man presents with a classic sporadic cancer pattern: advanced age, single tumor, and no family history. Most cancers in older adults result from somatic mutations that accumulate over decades in specific tissue cells. These mutations arise from environmental exposures, normal cellular aging processes, and DNA replication errors. The 35-year-old man's scenario is distinctly different—he carries a germline BRCA2 mutation confirmed by genetic testing, and his family shows the hallmark pattern of hereditary cancer syndrome with multiple affected relatives across generations. Choice A correctly identifies this fundamental distinction: sporadic cancer from accumulated somatic mutations versus hereditary cancer risk from an inherited germline mutation. Choice B incorrectly suggests both cases involve somatic mutations and dismisses the clear hereditary pattern in the second family. Choice C reverses the mutation types entirely—the older man doesn't have a germline mutation (no family history), and the younger man's BRCA2 mutation is germline, not somatic. Choice D contains a logical contradiction: somatic mutations by definition cannot be heritable since they're not present in reproductive cells, while germline mutations are always heritable. Remember: family history and age of onset are your primary clues for distinguishing hereditary versus sporadic cancer patterns on genetics exams.

Question 4

1. The patient has Li-Fraumeni syndrome, but it is confined to the tumor tissue.
2. The patient has somatic mosaicism for the TP53 mutation, meaning some but not all of their tissues are affected.
3. The germline test was a false negative, and should be repeated on a different tissue type like skin.
4. The patient has sporadic cancer caused by a somatic TP53 mutation; their hereditary risk is not elevated. (correct answer)

Explanation: When you encounter a question about genetic mutations found in tumors, you need to distinguish between germline (inherited) and somatic (acquired) mutations. This distinction is crucial for determining hereditary cancer risk and appropriate genetic counseling. In this case, the TP53 mutation was found in the tumor tissue but absent from the blood sample used for germline testing. This pattern indicates the mutation arose spontaneously in the cancer cells after birth, making it a somatic mutation. Since the patient's germline DNA (represented by the blood sample) lacks the mutation, they don't have Li-Fraumeni syndrome and their family members aren't at increased hereditary risk. Answer D is correct because a somatic TP53 mutation explains both the presence of the mutation in tumor tissue and its absence in germline testing. This represents sporadic cancer without elevated hereditary risk. Answer A is wrong because Li-Fraumeni syndrome is specifically a germline condition—if the germline test is negative, the patient doesn't have this syndrome. Answer B misapplies the concept of somatic mosaicism; true mosaicism would show the mutation in multiple tissue types, but here it's confined to the tumor. Answer C reflects a misunderstanding of germline testing—blood is an excellent sample for detecting germline mutations, and testing different tissues wouldn't change the result for a true germline variant. Remember: tumor-only mutations with negative germline testing typically indicate somatic mutations and sporadic cancer. Always correlate tumor findings with germline results to assess hereditary risk accurately.

Question 5

1. 100%
2. 50%
3. 25% (correct answer)
4. 0%

Explanation: This is a two-step probability calculation. First, the woman's son has a 50% (1/2) chance of inheriting the MSH2 mutation from his mother. Second, if he inherits the mutation, he then has a 50% (1/2) chance of passing it on to his child. The overall probability is the product of these two independent probabilities: P(son inherits) × P(child inherits from son) = (1/2) × (1/2) = 1/4, or 25%.

Question 6

1. His children have a 50% risk of inheriting the VHL mutation and associated cancer predisposition.
2. His children have no increased risk of VHL-associated cancers stemming from this specific paternal mutation. (correct answer)
3. His children's risk depends on whether the mutation is also present in his germline cells, which cannot be determined.
4. His children have an increased risk only if their mother also carries a somatic VHL mutation.

Explanation: The mutation was found in the tumor (somatic tissue) but not in blood leukocytes (representing the constitutional genome). This indicates the mutation is somatic, not germline. Somatic mutations occur in non-germline cells and are not heritable. Therefore, this specific mutation cannot be passed on to his children, and their risk is not increased because of it.

Question 7

1. A second, independent germline mutation in a different tumor suppressor gene.
2. A somatic mutation or loss of the remaining wild-type TP53 allele in a somatic cell. (correct answer)
3. The inherited germline TP53 mutation alone was sufficient to initiate tumorigenesis.
4. A somatic activating mutation in a proto-oncogene, which is independent of the TP53 gene status.

Explanation: Li-Fraumeni syndrome is a hereditary cancer predisposition syndrome caused by a germline mutation in one allele of the TP53 tumor suppressor gene. This represents the 'first hit'. According to the two-hit hypothesis for tumor suppressors, cancer initiation requires the inactivation of the second, remaining wild-type allele (the 'second hit'). This second hit is a somatic event occurring in a cell, leading to complete loss of tumor suppressor function and subsequent malignant transformation.

Question 8

1. The mutation is germline, and family members should be tested immediately.
2. The mutation is likely somatic, and therefore it does not imply an inherited cancer risk for relatives. (correct answer)
3. The mutation's origin cannot be determined, but it confirms the cancer is hereditary.
4. The mutation is likely a benign variant since it is not associated with a hereditary syndrome.

Explanation: Mutations in genes like PIK3CA are common 'driver' mutations that arise somatically within tumors. Because it's a tumor-only finding and not associated with a known hereditary syndrome, the default and most parsimonious assumption is that it is a somatic event. As such, it is confined to the tumor and is not heritable, meaning it has no direct implications for the cancer risk of family members. While a germline test could offer absolute certainty, it is not the most reasonable initial assumption.

Question 9

1. The VUS is confirmed to be pathogenic and the cause of cancer in the family because of the strong family history.
2. The VUS is certainly benign, and the family history of cancer is coincidental and unrelated to BRCA1.
3. The VUS is a somatic mutation and has no implications for the patient's sisters or other family members.
4. The VUS is a germline variant, but its contribution to cancer risk is unknown and it should not be used for clinical decisions. (correct answer)

Explanation: When you encounter questions about variants of uncertain significance (VUS) in genetics, focus on the fundamental principle that a VUS means exactly what it says: the clinical significance is unknown and cannot be determined from current evidence. The correct approach to this VUS is option D. Since the variant was found in both tumor tissue and blood (germline), it's inherited and could potentially be passed to family members. However, because it's classified as a VUS, we cannot determine whether it actually increases cancer risk. The strong family history of breast and ovarian cancer is concerning, but it doesn't change the VUS classification—clinical decisions should only be based on established pathogenic variants, not on VUS combined with family history assumptions. Let's examine why the other options are incorrect. Option A makes the critical error of assuming family history can reclassify a VUS as pathogenic—this is not how variant classification works and could lead to inappropriate medical decisions. Option B incorrectly concludes the variant is benign; a VUS could eventually be reclassified as either pathogenic or benign with more data, so dismissing it entirely is premature. Option C mischaracterizes the variant as somatic when the germline testing clearly shows it's inherited. Remember this key principle for genetics questions: VUS classification cannot be changed by family history alone. Only functional studies, population data, and other scientific evidence can reclassify variants. When you see VUS in a question, look for the answer choice that maintains uncertainty rather than jumping to definitive conclusions.

Question 10

1. Sequence the BRCA1 gene from the tumor tissue to confirm it caused the cancer.
2. Perform a multigene panel test on DNA extracted from a blood sample. (correct answer)
3. Analyze the patient's saliva for common environmental mutagens.
4. Sequence the tumor genome to identify all somatic driver mutations for targeted therapy.

Explanation: To determine if a cancer is due to a hereditary predisposition, one must test for a germline mutation. Germline mutations are present in all cells of the body, so a constitutional sample like blood (or saliva) is used. A multigene panel is appropriate because several genes can predispose to early-onset breast cancer. Testing only the tumor (Choice A and D) would identify somatic mutations but could not distinguish them from germline mutations without a constitutional comparison. Choice C is not a genetic test.

Question 11

1. Loss of heterozygosity at the MLH1 locus.
2. A pathogenic point mutation in the MSH2 gene.
3. Hypermethylation of the MLH1 gene promoter. (correct answer)
4. The presence of a concurrent KRAS mutation.

Explanation: While MSI-H is a hallmark of Lynch syndrome, it can also occur in sporadic cancers. The most common mechanism for sporadic MSI-H tumors is the epigenetic silencing of the MLH1 gene via hypermethylation of its promoter region. This is a somatic event that is not heritable. Loss of heterozygosity (A) and point mutations (B) can be the 'second hit' in a germline case or part of a two-hit somatic process, so they are less specific. A KRAS mutation (D) is a common event in colorectal cancer but does not help distinguish between germline and sporadic MSI-H origin.

Question 12

1. The individual is at increased risk of developing leukemia, and each of their offspring has a 50% chance of inheriting this risk.
2. The individual will develop cancer in multiple organ systems, and their offspring will not be affected.
3. The individual is at increased risk for hematologic malignancies, but their offspring have no increased risk from this mutation. (correct answer)
4. The individual will remain unaffected as the mutation is in a single cell, but their offspring are at high risk for inherited cancers.

Explanation: A somatic mutation affects only the individual in whom it occurs and is not heritable. Since the mutation occurred in a hematopoietic stem cell, it will be passed on to all of its daughter cells, creating a clone of mutated blood cells. This clonal expansion increases the risk of hematologic malignancies (like leukemia or lymphoma) for that individual. However, because it is a somatic mutation, it is not present in the germline cells and cannot be passed to offspring.

Question 13

1. His children have a 50% risk of inheriting the VHL mutation and associated cancer predisposition.
2. His children have no increased risk of VHL-associated cancers stemming from this specific paternal mutation. (correct answer)
3. His children's risk depends on whether the mutation is also present in his germline cells, which cannot be determined.
4. His children have an increased risk only if their mother also carries a somatic VHL mutation.

Explanation: The mutation was found in the tumor (somatic tissue) but not in blood leukocytes (representing the constitutional genome). This indicates the mutation is somatic, not germline. Somatic mutations occur in non-germline cells and are not heritable. Therefore, this specific mutation cannot be passed on to his children, and their risk is not increased because of it.

Question 14

1. A germline mutation that was present in an ancestor and has been inherited by many descendants. (correct answer)
2. A de novo mutation that has an unusually high rate of occurrence in this population's germline.
3. A somatic mutation that is frequently induced by a local environmental factor.
4. A benign polymorphism that has recently acquired pathogenicity due to gene-environment interactions.

Explanation: When you encounter genetics questions about isolated populations and founder effects, focus on understanding how genetic variants spread through populations over time. A founder effect occurs when a small group establishes a new population, carrying only a subset of the original population's genetic diversity. The correct answer is A because founder effects specifically involve variants that were present in founding ancestors and subsequently inherited by their descendants. In this scenario, one or more founders of the isolated population carried the pathogenic APC variant in their germline (reproductive cells). Over generations, this variant became disproportionately common due to the limited genetic diversity and potential inbreeding within the small, isolated group. Option B is incorrect because a founder effect doesn't involve unusually high mutation rates. The variant isn't repeatedly arising de novo; it's being inherited from a common ancestor. Option C is wrong because founder effects involve germline inheritance, not somatic mutations caused by environmental factors. Somatic mutations occur in non-reproductive cells and aren't passed to offspring. Option D is incorrect because the variant was already pathogenic when introduced by the founders – it didn't become harmful due to recent environmental interactions. Remember this key distinction: founder effects always involve inherited variants from ancestors, while high population frequencies result from limited genetic diversity in the founding group, not from new mutations or environmental factors. When you see "founder effect" in a question, immediately think about ancestral inheritance patterns rather than new mutation events.

Question 15

1. Inherited activating mutations in proto-oncogenes are often incompatible with embryonic development. (correct answer)
2. A single mutated copy of a proto-oncogene is not sufficient to increase cancer risk.
3. Proto-oncogenes are physically smaller genes and thus present a smaller target for mutation.
4. The cellular DNA repair machinery is much more effective at correcting mutations in proto-oncogenes.

Explanation: When you encounter questions about hereditary cancer syndromes, think about the fundamental difference between oncogenes and tumor suppressor genes, and how mutations in each affect normal development and cellular function. The correct answer is A because inherited activating mutations in proto-oncogenes often cause severe developmental problems that are incompatible with life. Proto-oncogenes normally promote controlled cell growth and division during development. When these genes are constitutively activated from conception, they can cause excessive, uncontrolled cell proliferation throughout embryonic development, leading to embryonic lethality or severe developmental abnormalities. This is why we rarely see inherited oncogene mutations in cancer families—affected embryos typically don't survive to birth. Option B is incorrect because oncogenes are dominant—a single activated copy is sufficient to contribute to cancer development. This is the opposite of tumor suppressor genes, which typically require both copies to be inactivated. Option C is wrong because gene size doesn't determine mutation frequency in hereditary cancer syndromes. Both proto-oncogenes and tumor suppressor genes vary widely in size, and this physical characteristic doesn't explain the epidemiological pattern. Option D is incorrect because DNA repair machinery doesn't preferentially target proto-oncogenes over tumor suppressor genes. Repair mechanisms work on DNA damage regardless of the gene type. Remember this key pattern: inherited cancer syndromes typically involve tumor suppressor genes (like BRCA1, RB1) because losing gene function is more developmentally tolerable than gaining excessive oncogenic function. When studying cancer genetics, always consider whether mutations cause loss or gain of function and their developmental consequences.

Question 16

1. A germline mutation responsible for a melanoma predisposition syndrome.
2. A somatic mutation that occurred early in tumorigenesis and was clonally propagated during metastasis. (correct answer)
3. Two independent somatic mutations that occurred separately in the liver and brain after metastasis.
4. A benign polymorphism that is common in the patient's ethnic background and unrelated to the cancer.

Explanation: The absence of the mutation in normal tissue confirms it is somatic, not germline. The presence of the identical mutation in two distinct metastatic sites makes it highly probable that it was present in the original primary tumor and was passed down to all daughter cells that formed the metastases. This indicates it was an early 'driver' mutation that was clonally expanded. It is extremely unlikely that the same mutation would occur independently in two different locations.

Question 17

1. Loss of heterozygosity at the MLH1 locus.
2. A pathogenic point mutation in the MSH2 gene.
3. Hypermethylation of the MLH1 gene promoter. (correct answer)
4. The presence of a concurrent KRAS mutation.

Explanation: While MSI-H is a hallmark of Lynch syndrome, it can also occur in sporadic cancers. The most common mechanism for sporadic MSI-H tumors is the epigenetic silencing of the MLH1 gene via hypermethylation of its promoter region. This is a somatic event that is not heritable. Loss of heterozygosity (A) and point mutations (B) can be the 'second hit' in a germline case or part of a two-hit somatic process, so they are less specific. A KRAS mutation (D) is a common event in colorectal cancer but does not help distinguish between germline and sporadic MSI-H origin.

Question 18

1. A germline mutation responsible for a melanoma predisposition syndrome.
2. A somatic mutation that occurred early in tumorigenesis and was clonally propagated during metastasis. (correct answer)
3. Two independent somatic mutations that occurred separately in the liver and brain after metastasis.
4. A benign polymorphism that is common in the patient's ethnic background and unrelated to the cancer.

Explanation: The absence of the mutation in normal tissue confirms it is somatic, not germline. The presence of the identical mutation in two distinct metastatic sites makes it highly probable that it was present in the original primary tumor and was passed down to all daughter cells that formed the metastases. This indicates it was an early 'driver' mutation that was clonally expanded. It is extremely unlikely that the same mutation would occur independently in two different locations.

Question 19

1. A second, independent germline mutation in a different tumor suppressor gene.
2. A somatic mutation or loss of the remaining wild-type TP53 allele in a somatic cell. (correct answer)
3. The inherited germline TP53 mutation alone was sufficient to initiate tumorigenesis.
4. A somatic activating mutation in a proto-oncogene, which is independent of the TP53 gene status.

Explanation: Li-Fraumeni syndrome is a hereditary cancer predisposition syndrome caused by a germline mutation in one allele of the TP53 tumor suppressor gene. This represents the 'first hit'. According to the two-hit hypothesis for tumor suppressors, cancer initiation requires the inactivation of the second, remaining wild-type allele (the 'second hit'). This second hit is a somatic event occurring in a cell, leading to complete loss of tumor suppressor function and subsequent malignant transformation.

Question 20

1. 100%
2. 50%
3. 25% (correct answer)
4. 0%

Explanation: This is a two-step probability calculation. First, the woman's son has a 50% (1/2) chance of inheriting the MSH2 mutation from his mother. Second, if he inherits the mutation, he then has a 50% (1/2) chance of passing it on to his child. The overall probability is the product of these two independent probabilities: P(son inherits) × P(child inherits from son) = (1/2) × (1/2) = 1/4, or 25%.